Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd has submitted its Annual Report for FY 2024-25 along with the notice for its 19th Annual General Meeting, to be held on September 30, 2025 at 11:30 AM via video conferencing. The company is in the business of manufacturing pharmaceutical products and formulations, and has a wholly owned subsidiary called Mansa Print & Publishers Limited. Several board changes occurred during the year, including a new CFO (Saruchi Gupta from May 2024), a new Company Secretary (Harshita Aggarwal from March 2025), and changes among Independent Directors. The AGM agenda includes adopting FY25 financial statements, re-appointing Managing Director Rajesh Gupta (who retires by rotation), ratifying Cost Auditor remuneration of Rs. 80,000 for FY 2025-26, and appointing M/s Anil Negi & Company as Secretarial Auditors for a 5-year term. Notably, the company is seeking shareholder approval to REDUCE the remuneration of both MD Rajesh Gupta (to a maximum CTC of Rs. 1 lakh per month) and Whole-time Director Saruchi Gupta (to Rs. 50,000 per month), effective October 1, 2025. The company explicitly stated it suffered losses due to a sharp rise in material costs, supply chain disruptions, and delayed payments from State Medical Corporations.
The proposed cut in MD and Whole-time Director pay is a clear signal of financial stress, even though the company frames it as cost rationalization. Retail investors should look closely at the financial statements in the annual report to assess the actual scale of losses, debtor quality (especially government receivables), and whether cost-control steps are translating into recovery. This is a high-risk, small-cap pharmaceutical name where promoter pay cuts typically reflect weak profitability rather than goodwill gestures.